Published in Antivir Ther on August 01, 2004
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV-infected individuals. J Immunol (2008) 1.21
An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J (2009) 0.91
Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. PLoS One (2015) 0.75
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97
Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature (2009) 5.00
Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell (2013) 3.92
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2009) 3.58
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol (2003) 2.87
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest (2009) 2.85
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity (2013) 2.79
Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol (2004) 2.39
TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity (2008) 2.37
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol (2005) 2.31
Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol (2010) 2.30
Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol (2005) 2.16
Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol (2010) 2.13
Cholinergic basal forebrain neurons burst with theta during waking and paradoxical sleep. J Neurosci (2005) 2.12
siRNA and isRNA: two edges of one sword. Mol Ther (2006) 2.02
New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. Rev Esp Cardiol (Engl Ed) (2011) 2.01
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol (2004) 1.85
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell (2013) 1.82
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol (2002) 1.76
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem (2004) 1.61
Approaching the RNA ligand for RIG-I? Immunol Rev (2009) 1.57
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res (2005) 1.49
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 1.47
SiRNA delivery with exosome nanoparticles. Nat Biotechnol (2011) 1.46
Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol (2011) 1.46
Signaling mechanisms underlying reversible, activity-dependent dendrite formation. Neuron (2002) 1.45
Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res (2003) 1.44
Sleep-wake related discharge properties of basal forebrain neurons recorded with micropipettes in head-fixed rats. J Neurophysiol (2004) 1.42
IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol (2004) 1.40
Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth. J Virol (2004) 1.34
Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol (2004) 1.32
Plasmacytoid dendritic cells: the key to CpG. Hum Immunol (2002) 1.28
The chase for the RIG-I ligand--recent advances. Mol Ther (2010) 1.27
Papillomaviruses: different genes have different histories. Trends Microbiol (2005) 1.27
Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem (2008) 1.27
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol (2009) 1.25
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep (2006) 1.24
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23
T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol (2006) 1.23
Ubiquitin protein ligase Nedd4 binds to connexin43 by a phosphorylation-modulated process. J Cell Sci (2006) 1.21
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 1.19
Cell-type specific modulation of intrinsic firing properties and subthreshold membrane oscillations by the M(Kv7)-current in neurons of the entorhinal cortex. J Neurophysiol (2007) 1.18
Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol (2008) 1.18
Morphological and electrophysiological properties of lateral entorhinal cortex layers II and III principal neurons. J Comp Neurol (2005) 1.18
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res (2013) 1.17
Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol (2002) 1.14
RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids. EMBO J (2012) 1.14
Rhythmically discharging basal forebrain units comprise cholinergic, GABAergic, and putative glutamatergic cells. J Neurophysiol (2003) 1.14
Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology (2004) 1.13
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer (2008) 1.12
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol (2003) 1.12
Multiple evolutionary mechanisms drive papillomavirus diversification. Mol Biol Evol (2007) 1.10
Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer (2012) 1.10
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
Human papillomavirus and p16 expression in inverted papillomas of the urinary bladder. Cancer Lett (2009) 1.08
Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine (2008) 1.07
Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene (2003) 1.07
Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol (2009) 1.07
CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol (2005) 1.06
Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol (2006) 1.06
TRPC channels underlie cholinergic plateau potentials and persistent activity in entorhinal cortex. Hippocampus (2011) 1.06
Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res (2011) 1.06
Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res (2009) 1.05
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. Vaccine (2009) 1.05
Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol (2009) 1.04
Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev (2012) 1.04
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04
Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res (2007) 1.04
Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands. J Immunol (2007) 1.02
RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol (2008) 1.01
MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families. Cancer Res (2010) 1.01
Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol (2005) 0.99
Turning tumors into vaccines: co-opting the innate immune system. Immunity (2013) 0.99
Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology (2007) 0.98
Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther (2012) 0.98
The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol (2002) 0.98
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer (2006) 0.98
Increased persistent sodium currents in rat entorhinal cortex layer V neurons in a post-status epilepticus model of temporal lobe epilepsy. Epilepsia (2003) 0.97
Fine gating properties of channels responsible for persistent sodium current generation in entorhinal cortex neurons. J Gen Physiol (2002) 0.97
CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol (2003) 0.97
Analysis of plasmacytoid and myeloid dendritic cells in nasal epithelium. Clin Vaccine Immunol (2006) 0.97
Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res (2010) 0.96